Αρχική World News FDA Approves First Immunotherapy Treatment For Breast Cancer

FDA Approves First Immunotherapy Treatment For Breast Cancer

The FDA has fast-tracked approval of a-first-of-its-kind immunotherapy treatment for breast cancer.This new treatment uses two different types of cancer therapy: Abraxane, a type of chemotherapy, and Tecentriq (generic name atezolizumab), a type of immunotherapy. Tecentriq has already been approved to treat certain kinds of urinary and lung cancers.The new treatment is specifically for triple negative breast cancer (TNBC), a notoriously aggressive form of the disease.TNBCPhoto: Adobe Stock/andreaobzerova
In TNBC, the cancerous cells don’t have receptors for estrogen, progesterone, or the protein HER-2/neu, all of which fuel cancer growth. This means doctors can’t use hormone therapy in addition to other treatments to target the cancerous cells, leaving them with one less tool in their arsenal.Anywhere from 10% to 20% of women diagnosed with breast cancer have TNBC. Women who are Hispanic or African-American, have the BRCA1 gene mutation, and/or are diagnosed with breast under age 50 are more likely to have TNBC, and the survival rate for TNBC is lower than other breast cancers.This therapy regimen is used on TNBC that can’t be removed with surgery and is either locally advanced or metastatic. The tumors must also have a protein called PD-L1 in order for the treatment to work properly. About 20% of TNBC cancer have the protein.How it worksPhoto: Adobe Stock/peckyhyong
The immune system on its own typically views cancerous cells as part of the body, so it doesn’t attack them. This therapy changes that.First, chemotherapy damages the cancer cells. Then, Tecentriq is administered, and this attaches to the cancer cells and disables the PD-L1 protein, which protects the cell from the immune system. Now that the immune system sees the cancer as an invader, it attacks.Chemo is given every week, while Tecentriq is given intravenously every other week.Accelerated ApprovalPhoto: Adobe Stock/freshidea
A study published in October of 2018 in The New England Journal Of Medicine prompted the accelerated approval of this treatment. The study found that the therapy regimen lengthened the amount of time that a patient could survive without their cancer worsening. For some women, their survival was extended by 10 months, and the risk of cancer becoming metastatic dropped by up to 40%.“This is the first time immunotherapy has worked in such a difficult-to-treat cancer, and is a huge step forward for these breast cancer patients,” said lead author of the study, Dr. Peter Schmid.An “accelerated approval” by the FDA is contingent upon future successful trials. For this treatment, a final report on the drug’s efficacy is due to the FDA by September of 2020. If the drug is considered beneficial, a traditional FDA approval will be given. If not, the drug could be pulled.Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...
- Advertisment -

Ροή Ειδήσεων

EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab

On 25 February 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...

Rare Disease Day: Raising Awareness for Rare Cancers

Every year on the last day of February, the world recognizes rare diseases—a day now known as Rare Disease Day. Rare diseases affect approximately 25...

Oncotype DX Breast Cancer Test May Be Less Accurate for Black Patients

February 26, 2021, by NCI Staff A sample of an Oncotype DX Breast Recurrence Score report. Credit: Adapted from image provided courtesy of Genomic Health The Oncotype...

Increase in Node-Positive and Stage III Breast Cancer After Two Months Screening Interruption Due to COVID-19 Pandemic

An increase in node-positive and stage III breast cancer after two months interruption in breast cancer screening due to COVID-19 pandemic was reported by...

Breast Cancer Survivor Opens Her Own Business 17 Years After Beating the Disease

The height of the pandemic may not be everyone’s ideal time to try and open a business. With restrictions limiting consumerism and Americans across...

The Late Alex Trebek’s Wardrobe Is Being Given to Homeless Men and Former Inmates

Alex Trebek, the late host of Jeopardy!, passed away on November 8th, 2020, at the age of 80, after a battle with pancreatic cancer....